CUSTOMIZED CANCER TREATMENT
Elevating advanced cancer care through empowered physician choices.
Reduce the risk of treatment failure as well as toxicities.
About GeneMaster DxTM
Breakthrough Technology for Refractory, Metastatic Solid Organ Cancers
Multi-platform tumor profiling test
GeneMaster DxTM is a multi-platform tumor profiling test which unravels the molecular and functional status of the cancer to identify and insightfully target the tumor's vulnerabilities.
Reduce The Risk of treatment failure as well as toxicities
GeneMaster DxTM provides direct tumor derived evidence which enables the physician to customize treatment options for each patient with unprecedented precision to reduce the risk of treatment failure as well as toxicities.
Clinically
Validated
The clinical utility of GeneMaster DxTM has been ascertained through a Phase - II / III open label single arm clinical trial.
PFS (at 90 days): 93.9%, DCR: 90.5% and ORR: 42.9%.
A Key Benefit For Targeted Therapy
Through personalized treatment / targeted therapy, physicians can select drugs that are more likely to be effective based on the patient’s genetic makeup and molecular profile.
Why GeneMaster Dx TM
Minimized Side Effects
Optimized Drug Selection
Reduced Treatment Duration
Higher Treatment Success Rates
The Resilient Trial
Phase – II / III open-label single arm clinical trial (CTRI/2018/02/011808).
